Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Tuesday, April 5, 2011

PlantPharm Biomed on Target to Introduce First Plant-Based Hepatitis B Vaccine

PlantPharm Biomed, a leader in plant-derived biomanufacturing, is on the cusp of introducing one of the first Plant-Made Pharmaceuticals (PMPs) with the release of an oral Hepatitis B vaccine proven to work in human subjects in a double-blind, placebo controlled Phase I clinical trial. The company is currently seeking FDA approval of the product, with other Plant-Made Pharmaceuticals products to follow.

Plant-Made Pharmaceuticals offer a faster, lower cost, more efficient method of producing pharmaceuticals, however, the industry has been struggling for years to find a method of production that is safe and effective. To achieve success, pharmaceutical proteins in plants must be grown in a zero-tolerance, 100% containment method for the public safety, with no potential to co-mingle with the food or seed supply. PlantPharm Biomed developed a proprietary, closed-environment growing system that has been perfected in cooperation with NASA. This biomanufacturing technology includes 30 patents and registrations worldwide, and the controlled environment production of fast growth, pathogen-free seed potatoes has been perfected by the company for more than a decade. PlantPharm is pleased to announce that the technology is now ready for use in biomanufacturing Plant-Made Pharmaceuticals.

Read complete press release here

No comments:

Post a Comment